These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33945995)

  • 21. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
    Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
    J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
    Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
    Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
    Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH
    Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
    Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
    Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new oncolytic
    Ahmed J; Chard LS; Yuan M; Wang J; Howells A; Li Y; Li H; Zhang Z; Lu S; Gao D; Wang P; Chu Y; Al Yaghchi C; Schwartz J; Alusi G; Lemoine N; Wang Y
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.
    Weibel S; Raab V; Yu YA; Worschech A; Wang E; Marincola FM; Szalay AA
    BMC Cancer; 2011 Feb; 11():68. PubMed ID: 21320309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
    Zhao Y; Croft M
    Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.
    Nguyen DH; Chen NG; Zhang Q; Le HT; Aguilar RJ; Yu YA; Cappello J; Szalay AA
    Mol Ther; 2013 Nov; 21(11):2054-62. PubMed ID: 23765443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer.
    Tysome JR; Wang P; Alusi G; Briat A; Gangeswaran R; Wang J; Bhakta V; Fodor I; Lemoine NR; Wang Y
    Hum Gene Ther; 2011 Sep; 22(9):1101-8. PubMed ID: 21361787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in gene therapy using oncolytic vaccinia virus as vectors.
    Yang X; Huang B; Deng L; Hu Z
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2433-2440. PubMed ID: 30293118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.
    Worschech A; Chen N; Yu YA; Zhang Q; Pos Z; Weibel S; Raab V; Sabatino M; Monaco A; Liu H; Monsurró V; Buller RM; Stroncek DF; Wang E; Szalay AA; Marincola FM
    BMC Genomics; 2009 Jul; 10():301. PubMed ID: 19583830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
    Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
    Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
    Adelfinger M; Gentschev I; Grimm de Guibert J; Weibel S; Langbein-Laugwitz J; Härtl B; Murua Escobar H; Nolte I; Chen NG; Aguilar RJ; Yu YA; Zhang Q; Frentzen A; Szalay AA
    PLoS One; 2014; 9(8):e104337. PubMed ID: 25093734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
    Kurosaki H; Nakatake M; Sakamoto T; Kuwano N; Yamane M; Ishii K; Fujiwara Y; Nakamura T
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic vaccinia virus and cancer immunotherapy.
    Xu L; Sun H; Lemoine NR; Xuan Y; Wang P
    Front Immunol; 2023; 14():1324744. PubMed ID: 38283361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.